Biomea Fusion, Inc. Common Stock
$1.79
$0.05 (+2.87%)
$1.72Day Range$1.83
Key Statistics
Market Cap
$129.75M
Shares Outstanding
72.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 16, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$1.78
Day High
$1.83
Day Low
$1.72
Volume
1.37M
VWAP
$1.78
Prev Close
$1.74
Transactions
--
Acc. Volume
--
About Biomea Fusion, Inc. Common Stock
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
PHARMACEUTICAL PREPARATIONSSIC 283437 employees1599 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070(650) 980-9099IPO Apr 16, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001840439
- Composite FIGI
- BBG00YS4WDC9
- Share Class FIGI
- BBG00YS4WDD8
- Ticker Root
- BMEA
- SIC Code
- 2834
About Biomea Fusion, Inc. Common Stock (BMEA) Stock
Biomea Fusion, Inc. Common Stock (BMEA) closed the 2026-09-17 session at $1.79, up 2.87% versus the previous close (+0.05). The stock opened at $1.78 and traded between $1.72 and $1.83 during that session. Session trading volume was 1.4M shares. The volume-weighted average price (VWAP) is $1.78.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Biomea Fusion, Inc. Common Stock has a market capitalization of $129.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. BMEA is listed on the XNAS exchange. The company employs approximately 37 people. Biomea Fusion, Inc. Common Stock is headquartered in SAN CARLOS, CA. The recorded listing date is 2021-04-16.
On this page you can find market BMEA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.